Stocks and Investing
Stocks and Investing
Thu, August 3, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Liana Moussatos Maintained (UTHR) at Buy with Increased Target to $307 on, Aug 3rd, 2023
Liana Moussatos of Wedbush, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Increased Target from $305 to $307 on, Aug 3rd, 2023.
Liana has made no other calls on UTHR in the last 4 months.
There are 2 other peers that have a rating on UTHR. Out of the 2 peers that are also analyzing UTHR, 0 agree with Liana's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Liana
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Decreased Target to $280 on, Friday, April 21st, 2023
- Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $310 on, Monday, April 10th, 2023
Contributing Sources